Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

MabVax Therapeutics, Inc. And Memorial Sloan-Kettering Cancer Center Report On Potential Use Of Dual-Labeled Antibody To Detect And Guide Surgical Removal Of Pancreatic Cancer

November 18, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 19, 2014 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical stage oncology drug development company in conjunction with the Department of Radiology at Memorial Sloan-Kettering Cancer Center (MSKCC) presented results on the use of MabVax’s lead antibody development candidate…

Salk scientists deliver a promising one-two punch for lung cancer

November 18, 2014 – 5:00 pm | Edit Post

LA JOLLA–Scientists at the Salk Institute have discovered a powerful one-two punch for countering a common genetic mutation that often leads to drug-resistant cancers. The dual-drug therapy–with analogs already in use for other diseases–doubled the survival rate of mice with lung cancer and halted cancer in pancreatic cells.

Salk scientists deliver a promising one-two punch for lung cancer

November 18, 2014 – 5:00 pm | Edit Post

LA JOLLA–Scientists at the Salk Institute have discovered a powerful one-two punch for countering a common genetic mutation that often leads to drug-resistant cancers. The dual-drug therapy–with analogs already in use for other diseases–doubled the survival rate of mice with lung cancer and halted cancer in pancreatic cells.

Ignyta Announces RXDX-101 Presentations At The 2014 “Molecular Targets And Cancer Therapeutics” Conference

November 18, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the acceptance of two abstracts for poster presentations relating to RXDX-101, the companys proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The poster presentations will…

Mast Therapeutics Release: New Data From Nonclinical Heart Failure Study To Be Presented At American Heart Association Conference

November 18, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 19, 2014 /PRNewswire/ –Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that data from MST-188 (vepoloxamer), its lead product candidate, will be featured at the…

Ligand Pharmaceuticals Inc. Provides Highlights From Today???s Analyst Day Event

November 18, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–At an Analyst Day event held earlier today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the financial leverage in its business model, revenue growth opportunities and its portfolio of partnered assets and unpartnered development programs, as well as its Captisol formulation technology and its financial outlook through 2017.Help employers…

Freedom Meditech, Inc. Granted Key U.S. Patent Covering The ClearPath DS-120 Device And Method Of Use

November 18, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 19, 2014 /PRNewswire/ –Freedom Meditech, Inc. today announced it has received official notification from the United States Patent and Trademark Office that the company has been granted a key patent providing the protection of intellectual property covering the ClearPath DS-120 device and method…

Dr. Kenneth J. Widder Joins Quidel Corporation’s Board Of Directors

November 18, 2014 – 5:00 pm | Edit Post

SAN DIEGO, CA–(Marketwired – November 18, 2014) – Highlighted Links Quidel DHI

Mirati Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference

November 18, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 19, 2014 /PRNewswire/ –Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at

BioMed Realty Trust And Broad Institute Form Strategic Partnership To Promote Innovation And Collaboration Within The Life Science Industry

November 18, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 19, 2014 /PRNewswire/ –BioMed Realty Trust, Inc. (NYSE: BMR) and the Broad Institute of MIT and Harvard today announced a strategic partnership to foster innovation and promote relationships between academia and the life science industry…